Order Article Reprints

Cheng W-C, Shen Y-C, Chen C-L, Liao W-C, Chen C-H, Chen H-J, Tu C-Y, Hsia T-C. Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study. Cancers. 2023; 15(3):642. https://doi.org/10.3390/cancers15030642

Cheng, Wen-Chien, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, and Te-Chun Hsia. 2023. "Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study" Cancers 15, no. 3: 642. https://doi.org/10.3390/cancers15030642

Cheng, W. -C., Shen, Y. -C., Chen, C. -L., Liao, W. -C., Chen, C. -H., Chen, H. -J., Tu, C. -Y., & Hsia, T. -C. (2023). Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study. Cancers, 15(3), 642. https://doi.org/10.3390/cancers15030642